BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38133713)

  • 1. SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19.
    Wang YC; Tsai CH; Wang YC; Yen LC; Chang YW; Sun JR; Lin TY; Chiu CH; Chao YC; Chang FY
    Infection; 2024 Jun; 52(3):955-983. PubMed ID: 38133713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.
    Petrone L; Petruccioli E; Vanini V; Cuzzi G; Najafi Fard S; Alonzi T; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Antinori A; Vergori A; Caccamo N; Cantini F; Girardi E; Ippolito G; Grifoni A; Goletti D
    Clin Microbiol Infect; 2021 Feb; 27(2):286.e7-286.e13. PubMed ID: 33045370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.
    Ravindran R; McReynolds C; Yang J; Hammock BD; Ikram A; Ali A; Bashir A; Zohra T; Chang WLW; Hartigan-O'Connor DJ; Rashidi HH; Khan IH
    PLoS One; 2021; 16(7):e0254367. PubMed ID: 34242356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
    Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
    Front Immunol; 2021; 12():723585. PubMed ID: 34489974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.
    Gu T; Zhao S; Jin G; Song M; Zhi Y; Zhao R; Ma F; Zheng Y; Wang K; Liu H; Xin M; Han W; Li X; Dong CD; Liu K; Dong Z
    Front Immunol; 2020; 11():621441. PubMed ID: 33584719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
    Burbelo PD; Riedo FX; Morishima C; Rawlings S; Smith D; Das S; Strich JR; Chertow DS; Davey RT; Cohen JI
    J Infect Dis; 2020 Jun; 222(2):206-213. PubMed ID: 32427334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection.
    Petruccioli E; Najafi Fard S; Navarra A; Petrone L; Vanini V; Cuzzi G; Gualano G; Pierelli L; Bertoletti A; Nicastri E; Palmieri F; Ippolito G; Goletti D
    J Transl Med; 2021 Jun; 19(1):272. PubMed ID: 34174875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
    Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.
    Patra T; Meyer K; Geerling L; Isbell TS; Hoft DF; Brien J; Pinto AK; Ray RB; Ray R
    PLoS Pathog; 2020 Dec; 16(12):e1009128. PubMed ID: 33284859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in chemokine and growth factor levels may be useful biomarkers for monitoring disease severity in COVID-19 patients; a pilot study.
    Wolszczak-Biedrzycka B; Dorf J; Wojewódzka-Żelezniakowicz M; Żendzian-Piotrowska M; Dymicka-Piekarska V; Matowicka-Karna J; Maciejczyk M
    Front Immunol; 2023; 14():1320362. PubMed ID: 38239363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein.
    Nakayama EE; Kubota-Koketsu R; Sasaki T; Suzuki K; Uno K; Shimizu J; Okamoto T; Matsumoto H; Matsuura H; Hashimoto S; Tanaka T; Harada H; Tomita M; Kaneko M; Yoshizaki K; Shioda T
    Sci Rep; 2022 May; 12(1):8108. PubMed ID: 35577892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.
    Christenson RH; Hansel S; II'yasova D; Meyer WA; Puckrein G; Lee L; Landry LG; Akinboboye O
    J Appl Lab Med; 2024 May; 9(3):493-501. PubMed ID: 38384143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.